Acceleron Pharma
128 Sidney Street
Cambridge
Massachusetts
United States
412 articles about Acceleron Pharma
-
Merck announced that it will be laying off 143 people from the Cambridge, Massachusetts-based Acceleron.
-
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
-
Merck Completes Acquisition of Acceleron Pharma Inc.
11/22/2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the acquisition of Acceleron Pharma Inc. (Nasdaq: XLRN).
-
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
11/19/2021
Merck today announced the successful completion of the cash tender offer, through a subsidiary, Astros Merger Sub, Inc., for all of the outstanding shares of common stock of Acceleron Pharma Inc.
-
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
11/17/2021
Merck as amended (“HSR”), in connection with Merck’s pending acquisition of Acceleron Pharma Inc.
-
Acceleron Reports Third Quarter 2021 Financial Results
11/4/2021
Acceleron Pharma Inc. today reported financial results for the third quarter ended September 30, 2021.
-
The decision came after Avoro Capital Advisors, which owns a 7% stake in Acceleron, posted its objections to the deal.
-
Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to Acquire Acceleron Pharma Inc.
10/29/2021
Merck, known as MSD outside the United States and Canada, announced that it has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Merck’s pending acquisition of Acceleron Pharma Inc.
-
Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales
10/27/2021
Acceleron Announces Third Quarter 2021 REBLOZYL ® Net Sales
-
Bristol Myers Squibb is reportedly courting Canada's Aurinia Pharmaceuticals to strike a buyout deal.
-
Merck and Acceleron struck an $11.5 billion merger agreement, but before that, rare-disease focused Acceleron Pharma was wooed by multiple suitors, including pharma giant Bristol Myers Squibb.
-
Merck Begins Tender Offer to Acquire Acceleron Pharma Inc.
10/12/2021
Merck, known as MSD outside the United States and Canada, is commencing , through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Acceleron Pharma Inc. On Sept. 30, 2021, Merck announced that it had entered into a definitive agreement to acquire Acceleron..
-
Newly appointed CEO Rob Davis must find a way to balance Merck’s portfolio before investors get (even more) antsy. And he is looking to be aggressive.
-
Investment firm Avoro Capital has raised concerns that the $180 per-share price Merck is paying Acceleron Pharma undervalues the rare-disease focused company.
-
Merck to Acquire Acceleron Pharma Inc.
9/30/2021
Merck, known as MSD outside the United States and Canada, and Acceleron Pharma Inc., a publicly traded biopharmaceutical company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion.
-
Merck will acquire Acceleron for the expected $180 per share in cash for an approximate total equity value of $11.5 billion.
-
Reports emerged late Wednesday afternoon that Merck emerged as the winning suitor with a deal valued at about $11 billion.
-
The rumors had already been percolating as Acceleron’s stock has risen over the past 10 days from $130-a-share in mid-September to $167.65 as the market closed on Friday.
-
Acceleron Reports Second Quarter 2021 Financial Results
8/5/2021
Acceleron Pharma Inc., a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, reported financial results for the second quarter ended June 30, 2021.
-
Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales
7/28/2021
Acceleron Pharma Inc., a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced net sales of REBLOZYL® as reported by its global collaborator, Bristol Myers Squibb, were approximately $128 million for the second quarter ended June 30, 2021.